| Chronic cardio-metabolic disorders | T2DM | CKD | CVD |
---|---|---|---|---|
Men | ||||
 AUC (95% CI) * | ||||
  Original Follow-up 6y | 0.72 (0.69–0.75) | 0.65 (0.61–0.69) | 0.76 (0.72–0.79) | 0.73 (0.68–0.79) |
  Intercept adjusted Follow-up 6y | 0.72 (0.69–0.75) | 0.65 (0.60–0.69) | 0.76 (0.72–0.79) | 0.73 (0.68–0.79) |
  Original Follow-up 9y | 0.71 (0.68–0.74) | 0.66 (0.62–0.69) | 0.71 (0.67–0.74) | 0.71 (0.66–0.75) |
  Intercept adjusted Follow-up 9y | 0.71 (0.68–0.74) | 0.66 (0.62–0.70) | 0.71 (0.67–0.74) | 0.71 (0.66–0.75) |
 HL test | ||||
  Original Follow-up 6y | 6.87 (p value = 0.55) | 7.71 (p-value = 0.46) | 12.82 (p-value = 0.12) | 18 (p-value = 0.02) |
  Intercept adjusted Follow-up 6y | 7.21 (p-value = 0.51) | 7.34 (p-value = 0.5) | 13.53 (p-value = 0.09) | 18.3 (p-value = 0.02) |
  Original Follow-up 9y | 10.7 (p-value = 0.22) | 8.77 (p-value = 0.36) | 13.21 (p-value = 0.1) | 13.3 (p-value = 0.1) |
  Intercept adjusted Follow-up 9y | 11.0 (p-value = 0.2) | 8.7 (p-value = 0.37) | 12.54 (p-value = 0.13) | 14.2 (p-value = 0.08) |
Women | ||||
 AUC (95% CI)a | ||||
  Original Follow-up 6y | 0.73 (0.71–0.76) | 0.69 (0.66–0.73) | 0.71 (0.69–0.74) | 0.82 (0.78–0.86) |
  Intercept adjusted Follow-up 6y | 0.73 (0.71–0.75) | 0.69 (0.66–0.73) | 0.71 (0.69–0.73) | 0.82 (0.78–0.86) |
  Original Follow-up 9y | 0.72 (0.70–0.75) | 0.68 (0.65–0.72) | 0.70 (0.68–0.72) | 0.81 (0.76–0.85) |
  Intercept adjusted Follow-up 9y | 0.72 (0.70–0.75) | 0.68 (0.65–0.71) | 0.70 (0.68–0.73) | 0.81 (0.77–0.85) |
 HL test | ||||
  Original Follow-up 6y | 5.62 (p-value = 0.69) | 36.3 (p-value < 0.001) | 10.1 (p-value = 0.26) | 14.9 (p-value = 0.06) |
  Intercept adjusted Follow-up 6y | 5.62 (p-value = 0.69) | 36.3 (p-value < 0.001) | 10.1 (p-value = 0.26) | 14.9 (p-value = 0.06) |
  Original Follow-up 9y | 6.4 (p-value = 0.6) | 35.2 (p-value < 0.001) | 8.19 (p-value = 0.41) | 11.2 (p-value = 0.2) |
  Intercept adjusted Follow-up 9y | 6.4 (p-value = 0.6) | 35.1 (p-value < 0.001) | 8.19 (p-value = 0.41) | 11.2 (p-value = 0.2) |